Document is current
Any future updates will be listed below
-
Authors
Kaiser, Ulrich https://orcid.org/0000-0003-0321-5245
Kaiser, Florian
Schmidt, Jörg
Vehling-Kaiser, Ursula
Hitzenbichler, Florian
-
Funding
Funding for this research was provided by:
Universitätsklinikum Regensburg
- License Information
-
More Information
Article History
Received: 31 August 2024
Accepted: 2 December 2024
First Online: 7 December 2024
Declarations
:
: After consultation with the Ethics Committee of the University of Regensburg, no professional advice and consequently no vote by the Ethics Committee was required for the present study in accordance with Sect. 15 of the Professional Code of Conduct for Physicians in Bavaria.
: Not applicable.
: U.K., J.S., and U.VK. declare no competing interests; F.H. has received lecture fees from Pfizer, and travel expenses and congress fees have been covered by Tillotts Pharma and Gilead Sciences; F.K. has conducted consulting work for Elsevier, Astellas, GSK, MSD, Novartis, Pierre Fabre, Sanofi, and Servier.
